Racetam
Brivaracetam
SaveA high-affinity SV2A ligand and levetiracetam analog FDA-approved as adjunctive therapy for partial-onset seizures. Not used as a nootropic.
Quick verdict
A well-studied prescription anticonvulsant with strong RCT support for epilepsy. No nootropic applications — included for completeness in the racetam family.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Phase III trials demonstrated significant reduction in partial-onset seizure frequency versus placebo. 15–30x higher affinity for SV2A than levetiracetam. Generally better tolerated than levetiracetam with fewer behavioral side effects.
Benefits
- FDA-approved for partial-onset seizures
- Better tolerability profile than levetiracetam
- High affinity and selectivity for SV2A
Dosage notes
50–200 mg/day in twice-daily dosing (FDA-approved range for epilepsy).
Side effects
- Drowsiness
- Dizziness
- Fatigue
- Irritability
Who should be cautious
Prescription-only anticonvulsant. Do not discontinue abruptly. May cause psychiatric symptoms. Hepatic dose adjustment needed.
What this page cannot tell you
Included as a racetam-family compound but this is a dedicated anticonvulsant, not a cognitive enhancer.
Write a review
Sign in to write a review.